LivaNova (NASDAQ:LIVN) Stock Rating Lowered by The Goldman Sachs Group

LivaNova (NASDAQ:LIVN) was downgraded by stock analysts at The Goldman Sachs Group from a “buy” rating to a “hold” rating in a report released on Wednesday, MarketBeat Ratings reports. They currently have a $55.00 price target on the stock. The Goldman Sachs Group’s target price points to a potential upside of 7.36% from the stock’s previous close.

Several other equities research analysts have also commented on LIVN. Barclays boosted their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $59.71.

LivaNova Price Performance

NASDAQ:LIVN opened at $51.23 on Wednesday. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -13.17 and a beta of 0.95. The company has a 50 day moving average price of $52.47 and a 200-day moving average price of $45.35. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova has a 1-year low of $32.48 and a 1-year high of $58.91.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 EPS. Equities research analysts forecast that LivaNova will post 2.85 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LIVN. Invesco Ltd. boosted its position in shares of LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after acquiring an additional 902,447 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of LivaNova by 111.7% during the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after acquiring an additional 829,115 shares during the last quarter. Scopia Capital Management LP acquired a new position in shares of LivaNova during the 2nd quarter valued at about $36,657,000. Nuveen LLC acquired a new position in LivaNova in the first quarter valued at about $30,954,000. Finally, Artisan Partners Limited Partnership lifted its position in LivaNova by 112.9% in the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after buying an additional 661,480 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.